IngentaConnect A comparison of treatment with dithranol and calcipotriol on the ...

Authors: Wall¹; Poyner²; Menday³

Source: British Journal of Dermatology, Volume 139, Number 6, December 1998 , pp. 1005-1011(7)

Abstract:

In a multicentre, randomized, open study, 306 patients of either sex, over 18 years of age with stable chronic plaque psoriasis > 100 cm² in surface area, and who gave informed consent, applied Dovonex (calcipotriol) ointment (50 μg/g) twice daily or Dithrocream (short-contact dithranol) 0.1-2% for up to 3 months. The number of patients `cleared' or with `marked improvement' at the end of treatment were: investigators' assessment—calcipotriol 92 of 153 (60.1%); dithranol 67 of 131 (51.1%); odds ratio 1.44 [95% confidence interval (CI) 0.90, 2.31; P = 0.128]; patients' assessment—calcipotriol 93 of 153 (60.8%); dithranol 65 of 131 (49.6%); odds ratio 1.57 (95% CI 0.98, 2.52; P = 0.059). Significant improvement in patients' quality of life as assessed by the Psoriasis Disability Index (PDI) and the Sickness Impact Profile (SIP) were seen in both treatment groups. Reduction in the total mean score for PDI was 6.5 in the calcipotriol group (95% CI 4.4, 8.6; P = 0.001) and 3.7 in the dithranol group (95% CI 1.1, 6.3; P = 0.005). The reduction in the total mean score for SIP was 2.8 in the calcipotriol group (95% CI 1.4, 4.3; P < 0.001) and 1.7 in the dithranol group (95% CI 0.2, 3.1; P = 0.024). Calcipotriol treatment tended to have advantages over treatment with dithranol in improving quality of life.

Document Type: Original article

DOI: 10.1046/j.1365-2133.1998.02556.x

Affiliations: 1: The Health Centre, Hermitage Road, St Johns, Woking, Surrey GU21 1TD, U.K., 2: Queen's Park Medical Centre, Farrer Street, Stockton on Tees TS18 2AW, U.K., 3: Leo Pharmaceuticals, Longwick Road, Princes Risborough, Bucks HP27 9RR, U.K.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis